Biosafety assessment of delivery systems for clinical nucleic acid therapeutics
Nucleic acid therapeutics, which involve transferring exogenous genes inside target cells, are a promising clinical treatment option that can regulate gene expression at the transcriptional or post-transcriptional level. Ideally, this kind of treatment modality will not lead to an unwanted immune re...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Biosafety and Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590053622000258 |
| _version_ | 1828498896740941824 |
|---|---|
| author | Zhimin Li Li Zhang Kai Jiang Yijing Zhang Yonglin Liu Guang Hu Jie Song |
| author_facet | Zhimin Li Li Zhang Kai Jiang Yijing Zhang Yonglin Liu Guang Hu Jie Song |
| author_sort | Zhimin Li |
| collection | DOAJ |
| description | Nucleic acid therapeutics, which involve transferring exogenous genes inside target cells, are a promising clinical treatment option that can regulate gene expression at the transcriptional or post-transcriptional level. Ideally, this kind of treatment modality will not lead to an unwanted immune response. Compared with traditional treatment methods, nucleic acid therapeutics can achieve prolonged and stable curative effects. As an emerging treatment method, nucleic acid therapeutics have played an increasingly important role in clinical settings for the treatment of various conditions, including infectious diseases, cancer, immune-related diseases, and monogenetic diseases. To date, a large number of clinical trials have been conducted, and more than 30 nucleic acid drugs have been approved, highlighting the strong potential of this approach in clinical practice. Diverse carriers are used to protect nucleic acids from being degraded and to help them reach their targets accurately. However, some carriers are known to cause negative effects on the release and expression of nucleic acid drugs as well as adverse effects such as allergic reactions and accumulation in the liver. Therefore, biosafety assessment of delivery systems before their application in clinical settings is critical. In this review, we describe different delivery systems for nucleic acid drugs and discuss their biosafety in both preclinical and clinical studies, with particular focus on the carriers themselves, drug administration method, and overall treatment of the disease. |
| first_indexed | 2024-12-11T13:15:26Z |
| format | Article |
| id | doaj.art-aff2e0d5a69640c68eece6f0ae7cd144 |
| institution | Directory Open Access Journal |
| issn | 2590-0536 |
| language | English |
| last_indexed | 2024-12-11T13:15:26Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biosafety and Health |
| spelling | doaj.art-aff2e0d5a69640c68eece6f0ae7cd1442022-12-22T01:06:04ZengElsevierBiosafety and Health2590-05362022-04-0142105117Biosafety assessment of delivery systems for clinical nucleic acid therapeuticsZhimin Li0Li Zhang1Kai Jiang2Yijing Zhang3Yonglin Liu4Guang Hu5Jie Song6School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, ChinaSchool of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, ChinaInstitute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai 200240, ChinaInstitute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China; School of Life Sciences, Tianjin University, Tianjin 300350, ChinaSchool of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, ChinaInstitute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China; School of Biomedical Sciences, Hunan University, Changsha 410082, ChinaInstitute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China; Institute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China; Corresponding author: Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China; Institute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.Nucleic acid therapeutics, which involve transferring exogenous genes inside target cells, are a promising clinical treatment option that can regulate gene expression at the transcriptional or post-transcriptional level. Ideally, this kind of treatment modality will not lead to an unwanted immune response. Compared with traditional treatment methods, nucleic acid therapeutics can achieve prolonged and stable curative effects. As an emerging treatment method, nucleic acid therapeutics have played an increasingly important role in clinical settings for the treatment of various conditions, including infectious diseases, cancer, immune-related diseases, and monogenetic diseases. To date, a large number of clinical trials have been conducted, and more than 30 nucleic acid drugs have been approved, highlighting the strong potential of this approach in clinical practice. Diverse carriers are used to protect nucleic acids from being degraded and to help them reach their targets accurately. However, some carriers are known to cause negative effects on the release and expression of nucleic acid drugs as well as adverse effects such as allergic reactions and accumulation in the liver. Therefore, biosafety assessment of delivery systems before their application in clinical settings is critical. In this review, we describe different delivery systems for nucleic acid drugs and discuss their biosafety in both preclinical and clinical studies, with particular focus on the carriers themselves, drug administration method, and overall treatment of the disease.http://www.sciencedirect.com/science/article/pii/S2590053622000258Nucleic acid therapeuticsDelivery systemBiosafetyViral vectorLipidCarrier-free delivery |
| spellingShingle | Zhimin Li Li Zhang Kai Jiang Yijing Zhang Yonglin Liu Guang Hu Jie Song Biosafety assessment of delivery systems for clinical nucleic acid therapeutics Biosafety and Health Nucleic acid therapeutics Delivery system Biosafety Viral vector Lipid Carrier-free delivery |
| title | Biosafety assessment of delivery systems for clinical nucleic acid therapeutics |
| title_full | Biosafety assessment of delivery systems for clinical nucleic acid therapeutics |
| title_fullStr | Biosafety assessment of delivery systems for clinical nucleic acid therapeutics |
| title_full_unstemmed | Biosafety assessment of delivery systems for clinical nucleic acid therapeutics |
| title_short | Biosafety assessment of delivery systems for clinical nucleic acid therapeutics |
| title_sort | biosafety assessment of delivery systems for clinical nucleic acid therapeutics |
| topic | Nucleic acid therapeutics Delivery system Biosafety Viral vector Lipid Carrier-free delivery |
| url | http://www.sciencedirect.com/science/article/pii/S2590053622000258 |
| work_keys_str_mv | AT zhiminli biosafetyassessmentofdeliverysystemsforclinicalnucleicacidtherapeutics AT lizhang biosafetyassessmentofdeliverysystemsforclinicalnucleicacidtherapeutics AT kaijiang biosafetyassessmentofdeliverysystemsforclinicalnucleicacidtherapeutics AT yijingzhang biosafetyassessmentofdeliverysystemsforclinicalnucleicacidtherapeutics AT yonglinliu biosafetyassessmentofdeliverysystemsforclinicalnucleicacidtherapeutics AT guanghu biosafetyassessmentofdeliverysystemsforclinicalnucleicacidtherapeutics AT jiesong biosafetyassessmentofdeliverysystemsforclinicalnucleicacidtherapeutics |